AstraZeneca, Clinical Pharmacology & Safety Sciences, Melbourn Science Park, Melbourn SG8 6HB, United Kingdom.
AstraZeneca, Clinical Pharmacology & Safety Sciences, Melbourn Science Park, Melbourn SG8 6HB, United Kingdom.
Vaccine. 2022 Jan 21;40(2):192-195. doi: 10.1016/j.vaccine.2021.11.028. Epub 2021 Dec 2.
Biodistribution studies of adenovirus-based vaccines support their clinical development by evaluating their spread and persistence following in vivo administration. AZD1222 (ChAdox1 nCov-19) is a replication-deficient non-human adenovirus-vectored vaccine for coronavirus disease 2019. In this nonclinical study, the biodistribution of AZD1222 was assessed in mice for 29 days following intramuscular injection. Results show that AZD1222 was safe and well tolerated, with a spread that was largely confined to administration sites and the proximal sciatic nerve, with low levels observed in sites that are involved in rapid clearance of particulates by the reticuloendothelial system. Accordingly, levels of AZD1222 decreased from Day 2 to Day 29, indicating clearance. There were no quantifiable levels of AZD1222 in the blood, brain, spinal cord, and reproductive tissue, suggesting a lack of widespread or long-term distribution of AZD1222 vector DNA throughout the body following its administration.
腺病毒疫苗的生物分布研究通过评估其在体内给药后的传播和持久性来支持其临床开发。AZD1222（ChAdox1 nCov-19）是一种用于 2019 年冠状病毒病的复制缺陷型非人类腺病毒载体疫苗。在这项非临床研究中，在肌肉内注射后 29 天内评估了 AZD1222 在小鼠中的生物分布。结果表明，AZD1222 安全且耐受性良好，其传播范围主要局限于给药部位和近端坐骨神经，在网状内皮系统快速清除颗粒的部位观察到低水平。因此，AZD1222 的水平从第 2 天到第 29 天下降，表明其被清除。血液、大脑、脊髓和生殖组织中均未检测到可量化的 AZD1222 水平，这表明在给药后，AZD1222 载体 DNA 不会在全身广泛或长期分布。
